Mis tiroides (y mis hormonas en general) siempre han sido un caos. Hace años que intento que me receten T3, pero como los valores iniciales salen "bajitos pero normales", pues no hay manera, ni me miran cómo estoy de T3... Pero a mí, la única medicación para la tiroides que me funcionaba medio bien era la que contenía t3 y t4, que ahora aparte de ser difícil de encontrar, es que es imposible de pagar, así que ya ni lo intento... El Eutirox (T4) llevo años diciendo que no me hace nada... y ahora leo ésto.
Destaco estas frases: "Los presentes hallazgos están en linea con los estudios metabolómicos recientes que señalan un estado hipometabólico. Es como una forma suave de "síndrome de la enfermedad no tiroidea" y "síndrome de bajo T3" experimentado por un subgrupo de pacientes hipotiroideos que reciben una monoterapia de T4." Y aunque estresa que este estudio necesita ser confirmado y aumentado, habla de, en caso de confirmarse, una posible terapia con T3 y suplementos de ioduro. Tendré que pasárselo a algunos de mis médicos para que se lo mire
Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case–Control Study
Begoña Ruiz-Núñez1,2*, imageRabab Tarasse1, imageEmar F. Vogelaar3, imageD. A. Janneke Dijck-Brouwer1 and imageFrits A. J. Muskiet11Department of Laboratory Medicine, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
2Healthy Institute, Madrid, Spain
3European Laboratory of Nutrients, Bunnik, Netherlands
Chronic fatigue syndrome (CFS) is a heterogeneous disease with unknown cause(s). CFS symptoms resemble a hypothyroid state, possibly secondary to chronic (low-grade) (metabolic) inflammation. We studied 98 CFS patients (21–69 years, 21 males) and 99 age- and sex-matched controls (19–65 years, 23 males). We measured parameters of thyroid function, (metabolic) inflammation, gut wall integrity and nutrients influencing thyroid function and/or inflammation. Most remarkably, CFS patients exhibited similar thyrotropin, but lower free triiodothyronine (FT3) (difference of medians 0.1%), total thyroxine (TT4) (11.9%), total triiodothyronine (TT3) (12.5%), %TT3 (4.7%), sum activity of deiodinases (14.4%), secretory capacity of the thyroid gland (14.9%), 24-h urinary iodine (27.6%), and higher % reverse T3 (rT3) (13.3%). FT3 below the reference range, consistent with the “low T3 syndrome,” was found in 16/98 CFS patients vs. 7/99 controls (OR 2.56; 95% confidence interval = 1.00–6.54). Most observations persisted in two sensitivity analyses with more stringent cutoff values for body mass index, high-sensitive C-reactive protein (hsCRP), and WBC. We found possible evidence of (chronic) low-grade metabolic inflammation (ferritin and HDL-C). FT3, TT3, TT4, and rT3 correlated positively with hsCRP in CFS patients and all subjects. TT3 and TT4 were positively related to hsCRP in controls. Low circulating T3 and the apparent shift from T3 to rT3 may reflect more severely depressed tissue T3 levels. The present findings might be in line with recent metabolomic studies pointing at a hypometabolic state. They resemble a mild form of “non-thyroidal illness syndrome” and “low T3 syndrome” experienced by a subgroup of hypothyroid patients receiving T4 monotherapy. Our study needs confirmation and extension by others. If confirmed, trials with, e.g., T3 and iodide supplements might be indicated.
enlace: https://www.frontiersin.org/articles/10 ... 00097/full